GlaxoSmithKline plc (GSK) To Go Ex-Dividend on November 9th
GlaxoSmithKline plc (NYSE:GSK) announced a quarterly dividend on Thursday, October 26th, Wall Street Journal reports. Stockholders of record on Friday, November 10th will be given a dividend of 0.5037 per share by the pharmaceutical company on Thursday, January 11th. This represents a $2.01 annualized dividend and a dividend yield of 5.57%. The ex-dividend date of this dividend is Thursday, November 9th. This is an increase from GlaxoSmithKline plc’s previous quarterly dividend of $0.49.
GlaxoSmithKline plc has decreased its dividend by an average of 3.1% per year over the last three years. GlaxoSmithKline plc has a dividend payout ratio of 68.4% meaning its dividend is sufficiently covered by earnings. Analysts expect GlaxoSmithKline plc to earn $2.81 per share next year, which means the company should continue to be able to cover its $1.99 annual dividend with an expected future payout ratio of 70.8%.
Shares of GlaxoSmithKline plc (NYSE:GSK) opened at $36.15 on Friday. The company has a market cap of $88.99 billion, a P/E ratio of 12.75, a PEG ratio of 1.99 and a beta of 1.00. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline plc has a 12-month low of $35.86 and a 12-month high of $44.53.
TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-to-go-ex-dividend-on-november-9th/1677628.html.
GSK has been the topic of a number of research analyst reports. Zacks Investment Research lowered GlaxoSmithKline plc from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Morgan Stanley lowered GlaxoSmithKline plc from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. BidaskClub raised GlaxoSmithKline plc from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Finally, Argus reaffirmed a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline plc in a research report on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $44.33.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.